Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

AGI-1067. AtheroGenics.

Grant M Hatch¹

¹Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, Winnipeg, Canada. hatchgm@ms.umanitoba.ca

Current Opinion in Investigational Drugs (London, England : 2000)

|June 11, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Role of the Proteasome System in Shaping Cellular Immunological Characteristics and Its Impact in Modulating the Pathogenesis of Immune-Related Diseases.

Cells, tissues, organs·2026

Same author

Reduction in cardiolipin reduces expression of creatine transporter-1 and creatine transport in growing hCMEC/D3 human brain microvessel endothelial cells.

Frontiers in drug delivery·2025

Same author

Disrupted homeostasis in phytosterolemia: a hypothesis inspired by David Mymin, MD.

Pediatric research·2025

Same author

PI3K-dependent reprogramming of hexokinase isoforms controls glucose metabolism and functional responses of B lymphocytes.

iScience·2024

Same author

Reduced protein kinase C delta in a high molecular weight complex in mitochondria and elevated creatine uptake into Barth syndrome B lymphoblasts.

Journal of translational genetics and genomics·2024

Same author

Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndrome.

Nature metabolism·2023

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

AGI-1067, an oral vascular cell adhesion molecule-1 inhibitor, is being developed to prevent atherosclerosis and restenosis. Clinical trials are ongoing, with potential launch and significant sales predicted by 2005.

Area of Science:

Pharmacology
Cardiovascular Medicine
Drug Development

Background:

Atherosclerosis and restenosis are significant cardiovascular conditions.
VCAM-1 plays a role in the inflammatory processes underlying these diseases.
AGI-1067 is an investigational oral drug targeting VCAM-1 gene expression.

Purpose of the Study:

To evaluate the efficacy and safety of AGI-1067 for preventing and treating atherosclerosis and restenosis.
To assess AGI-1067's potential in post-angioplasty settings.

Main Methods:

Phase II clinical trials were conducted to assess AGI-1067.
Dosing was completed in early 2001 for restenosis and atherosclerosis trials.
Further Phase II trials (CART-2) were initiated in late 2001.

Related Experiment Videos

Main Results:

Clinical trials are ongoing, indicating continued development and evaluation.
Analyst predictions suggest a 2005 launch with substantial projected sales.
AtheroGenics is seeking marketing partnerships post-CART-2 trial completion.

Conclusions:

AGI-1067 shows promise as a novel therapeutic agent for cardiovascular diseases.
Ongoing clinical development and positive market projections support its potential.
Further research and strategic partnerships are anticipated for AGI-1067's market entry.